Neurodegenerative diseases affect millions of people globally and the increasing prevalence is a result of extended lifespans. These debilitating conditions cause damage to the neurons, which leads to problems with movement and cognition. One prominent feature is protein misfolding and aggregation in brain tissue. Since most animal models used to study the pathogenesis of neurodegeneration have been developed in mice, the Seeker desires an improved in vivo method to detect protein-protein interactions in the mouse brain.
This Theoretical Challenge requires only a written proposal.
Proteins are complex molecules that are essential for maintaining the structure and regulating the function of tissues and organs. Improper protein folding and subsequent aggregation of these misfolded proteins are thought to be crucial in the pathogenesis of neurodegenerative diseases such as Alzheimer’s, Huntington’s, and Parkinson’s. While the proteins involved and the locations of accumulation vary, more research is needed to define the role that these protein clusters play in disease development. The majority of studies are conducted in mouse models of neurodegeneration, thus the Seeker desires an improved in vivo method for the detection and quantitation of protein-protein interactions in the mouse brain.
This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker.
To receive an award, the Solvers will have to transfer their exclusive Intellectual Property (IP) rights to the Seeker. See the Challenge-Specific Agreement for full details.
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on December 6, 2017.
Late submissions will not be considered.
ABOUT THE SEEKER
We are an international and independent pharmaceutical company governed by a non-profit foundation, with headquarters in Suresnes, France. Since opening our first laboratory in 1954, we have been committed to therapeutic progress to serve patient needs with the help of healthcare professionals. We strive to provide future generations with a world where quality healthcare is available and accessible to all. Operating in 148 countries, we have 21,000 collaborators employed worldwide and a turnover of 4 billion euros in 2016. Entirely independent, we are able to reinvest 25% of our total revenue (excluding generics) into Research and Development, and all profits are used for further development. Corporate growth at Servier is driven by our continuous pursuit of innovation in five areas of excellence: cardiovascular and immune-inflammatory diseases, neuropsychiatric disorders, cancers and diabetes. We are a leading force in cardiology—number 2 in Europe, number 8 worldwide—and oncology has become a top priority in recent years; we also manufacture high-quality generic drugs.
Our three research centres are continuously involved in creating, testing, and developing new medicinal products, which are manufactured and packaged in our 15 production centres around the world. We have an active partnership policy in the field of biotechnology and we are investing in e-health through our internal WeHealth by Servier initiative. All our employees are driven by shared values and guided by a common vision. Together we share the passion of entrepreneurship and we are committed to therapeutic progress to serve patient needs. For more information, visit: www.servier.com.
What is a Theoretical IP Transfer Challenge?
An InnoCentive Theoretical Challenge builds upon an idea but is not yet a proof of concept. A solution to a Theoretical Challenge will solidify the Solver's concept with detailed descriptions, specifications and requirements necessary to bringing a good idea closer to becoming an actual product or service.
This Challenge is a Theoretical-IP Transfer Challenge, meaning that Solvers must relinquish all rights to the Intellectual Property (IP) for which they are awarded. By contrast, Theoretical-Licensing means that the Seeker is requesting non-exclusive rights to use the winning solution. For these forms of a Theoretical Challenge, Solvers that do not win retain the rights to their solution after the evaluation period is complete. The Seeker retains no rights to any IP not awarded.